- Nano cap Catabasis Pharmaceuticals (NASDAQ:CATB) is up 29% premarket on robust volume in response to the presentation of data from Part B of its Phase 2 clinical trial, MoveDMD, assessing edasalonexent in boys with Duchenne muscular dystrophy (DMD). The results were announced at the American Academy of Neurology 69th Annual Meeting in Boston.
- In January, the company reported that MoveDMD failed to show a treatment benefit over placebo. The functional data presented at AAN show a numerical improvement, but none are statistically significant since the study was not powered to demonstrate it for these parameters.
- DMD boys treated with edasalonexent for 12 weeks experienced a 50% slower rate of decline in the 10-meter walk/run test, a 45% slower rate of decline in time to stand and more than 50% reductions in the rates of decline in the 4-stair climb, North Star Ambulatory Assessment and Pediatric Outcomes Data Collection Instrument assessment.
- The company plans to report interim results from the open-label extension phase (Part C) of MoveDMD next quarter. It will determine the next development steps after completing additional data analyses.
- Edasalonexent inhibits a protein activated in DMD called NF-kB which plays a key role in inflammation and fibrosis.
- Previously: Catabasis Pharma 's edasalonexent flops in randomized portion of mid-stage DMD study; shares crater 58% after hours (Jan. 31)
- Now read: MannKind Corporation Needs A Merger
Original article